Introduction
The survival of all organisms depends on the dynamic control of energy metabolism during acute or prolonged shortage of nutrient supply. Over the past years, the 5 -adenosine monophosphate-activated protein kinase (AMPK) has emerged as an important regulator of ′ cellular energy homeostasis that coordinates metabolic pathways in order to balance nutrient supply with energy demand in mammalian cells. AMPK is a homolog of Snf1 kinase, a metabolic stress sensing kinase that is critical for yeast survival Saccharomyces cerevisiae under conditions of glucose starvation ( ). AMPK is an energy-sensing protein complex, activated in response to an Woods , 1994 et al. increase in the AMP:ATP ratio during hypoxia, starvation, glucose deprivation or muscle contraction ( ). AMPK Kahn , 2005 et al. integrates nutritional and hormonal signals to maintain cellular energy balance and execute appropriate metabolic functions (e.g., regulation of fatty acids partitioning between oxidative and biosynthetic pathways) in response to nutritional and environmental variations ( ). One mechanism by which AMPK regulates lipid metabolism is phosphorylation and inactivation of acetyl CoA Viollet , 2009 et al. carboxylase (ACC) , an important rate-controlling enzyme for the synthesis of malonyl-CoA. ACC is both a critical precursor for biosynthesis of fatty acids and a potent inhibitor of long-chain fatty acyl-CoA transport to mitochondria for -oxidation.
β Knockdown/knockout of ACC1 and ACC2 (predominantly expressed in liver and skeletal muscle, respectively), has been reported to cause continuous fatty acid oxidation, increased energy expenditure and reduced fat mass ( ; ; Abu-Elheiga , 2001 et al. Choi , 2007 et al. ) . But recent studies have reported limited effects of ACC2 deletion on fatty acid oxidation in skeletal muscle and Savage , 2006 et al. overall energy expenditure or adiposity ( ; ). These recent reports indicate that increased fatty acid Hoehn , 2010 et al. Olson , 2010 oxidation in skeletal muscle does not cause leanness and raises questions regarding the use of ACC2 inhibitors in the treatment of obesity.
However, the use of a small molecule direct AMPK activator A-769662 was shown to have beneficial effects on both hepatic steatosis and insulin resistance, thus emphasizing the potential therapeutic implications for AMPK activation in type 2 diabetes ( ). Cool , 2006 et al. Regardless, AMPK activation results in inhibition of energy-consuming biosynthetic pathways (such as fatty acid synthesis and adipocytes, cholesterol synthesis in the liver and insulin secretion from -cell) and activation of ATP-producing catabolic pathways (such β as fatty acid uptake and oxidation in multiple tissues, glycolysis in heart and mitochondrial biogenesis in muscle). AMPK also modulates transcription of specific genes involved in energy metabolism, thereby exerting long-term metabolic control ( ). It is Viollet , 2006 et al. also implicated in the central regulation of food intake and energy expenditure in response to hormonal cues including leptin, ghrelin and adiponectin. Thus, AMPK not only governs cellular energy, but regulates overall organismal bio-energetics by coordinating the response in and in-between tissues according to nutritional input. Its position at crossroads of energy metabolism makes AMPK an attractive therapeutic target in metabolic diseases, with its pharmaceutical potential in situations of insulin resistance already confirmed. It has therefore emerged as a promising new drug target for the treatment of metabolic disorders including obesity, Type 2 diabetes and cardiovascular disease.
Due to its role in maintaining energy balance, a dysfunction in AMPK signaling pathway may result in perturbations at the systemic level that contribute to development of metabolic disorders. In support, there is a strong correlation between low AMPK activation state, mainly due to over-nutrition and lack of exercise, and metabolic disorders associated with insulin resistance, obesity and sedentary lifestyle ( ). Furthermore, decreased AMPK activation is implicated in human metabolic disorders associated with Ruderman and Prentki, 2004 increased cancer risk. Numerous studies show links between AMPK and cancer, both at the organism and molecular levels. Although the contribution of AMPK to the etiology of these disorders is unclear, pharmacologic AMPK activators are effective in their treatment.
Interestingly, recent evidences indicate that AMPK participates in the regulation of non-metabolic processes such as cell growth, cell cycle progression and organization of the cytoskeleton ( ). Since, all these are highly energy-consuming processes, Williams and Brenman, 2008 AMPK s involvement is certain, due to its ability to directly sense and regulate cellular energy homeostasis. AMPK signaling pathway ' serves as a metabolic checkpoint in the cell, arresting cell growth in low energy status, such as low nutrient conditions . Moreover, recent studies in lower eukaryote demonstrated that AMPK is involved in the regulation of epithelial cell polarity and mitotic cell division ( ). Lee , 2007a et al. Although AMPK activation is an adaptive response to energy stress in numerous systems, AMPK plays a role in both physiological and pathophysiological states. Here, we review our understanding of AMPK inhibition in response to cellular and organismal energy challenges and describe the beneficial as well as adverse consequences of global AMPK modulation.
Structure and regulation of AMPK Structure and subunit composition
AMPK exists in the cell as a heterotrimeric complex with one catalytic ( , 63 kDa) and two regulatory subunits ( , 30kDa, and , 38 α β γ -63 kDa) in a 1 :1 :1 ratio ( ). The subunit contains a conventional serine/threonine kinase domain at the N-terminus followed α β γ Figure 1 α by an auto-inhibitory domain, and a C-terminus containing the domains required for binding of and subunits ( Townley and Shapiro, 2007 Xiao , 2007 et al. of the three AMPK subunits ( 1, 2, 1, 2, 1, 2, 3 with splice variants for the 2 and 3 isoforms adding to the diversity), encoded by α α β β γ γ γ γ γ distinct genes and theoretically leading to formation of at least 12 different complexes. These combinations confer different properties to the AMPK complexes through differences in subcellular localization and signaling functions ( ; ). Cheung , 2000 et al. Salt , 1998a Thus, the tissue-specific subunit composition may be important to determine a specialized cellular and systemic response to different metabolic stresses. Recent investigation of isoform composition of AMPK complexes in human skeletal muscle found that only 3 of the 12 potential AMPK complexes were present ( 2 2 1 2 2 3 1 2 1) and were activated differently, depending on exercise intensity and α β γ ≫α β γ =α β γ
duration (
). AMPK 1 catalytic subunit expression is relatively distributed across adipose tissue, pancreas, Birk and Wojtaszewski, 2006 α lung, spleen and kidney. Skeletal and cardiac muscles predominantly express AMPK 2 catalytic subunit. While the 1 subunit is α β ubiquitously expressed, AMPK 2 subunit is abundantly expressed in skeletal muscle and heart. Interestingly, expression of the 3 subunit β γ appears highly specific to glycolytic skeletal muscle whereas 1 and 2 show broad tissue distribution ( ). 
Allosteric regulation by AMP and ATP
AMPK is allosterically activated by AMP, which binds to the regulatory subunit, resulting in a 2 to 5 fold increase in activity γ compared to basal activity ( ). The degree of activation by AMP is markedly affected by nature of the catalytic and Hardie , 1999 et al. α regulatory iso-forms constituting the AMPK complex, illustrating the complexity of AMPK signaling regulation. The greatest scale of γ activation is observed in AMPK complexes containing the 2 and 2 subunits, while complexes containing the 3 isoform are only weakly induces a conformational change in the kinase domain that protects AMPK from dephosphorylation of Thr-172 ( ; Riek , 2008 et al. ;  ), favoring accumulation of the phosphorylated active form of AMPK (see below). Interestingly, it Sanders , 2007 et al. Suter , 2006 has been demonstrated that high concentrations of ATP oppose activation of the AMPK complex by AMP, suggesting that the allosteric sites bind AMP and ATP in a mutually exclusive manner ( ). Thus, AMPK can be considered more as a sensor of the Corton , 1995 et al. intracellular AMP/ATP ratio, rather than a direct sensor of AMP levels. AMP and ATP vary reciprocally in cells, due to the action of adenylate kinase (AMP ATP <-> 2ADP adenosine 5 -diphosphate ), thus, AMP: ATP ratio may be a more sensitive indicator of cellular
energy status than ADP: ATP ratio. The finding that AMPK activation is altered in contracting muscles from adenylate kinase-deficient mice also supports a role for adenylate kinase in generation of an AMPK activating signal ( proposed physiological role of the kinase as a sensor of cellular energy status. As it decreases during muscle contraction, phosphocreatine, rather than AMP, may be the key regulator of the AMPK system during short-term exercise.
Autoregulation of AMPK complexes
AMPK, like other protein kinases, autoregulates its own activity through structural elements, that directly block its catalytic site.
Within the catalytic subunit, a region that is C-terminal to the kinase domain appears to act as an auto-inhibitory domain (AID) by 
AID (
). In addition to the AID, it has been suggested that AMPK is also inhibited by an internal auto-inhibitory sequence Pang , 2008 et al. similar to the consensus recognition motif for AMPK substrates but lacking a phosphoryl-able amino acid. Scott and coworkers proposed that, in the absence of AMP, a pseudo-substrate sequence, within the 2 CBS2 sub-domain, binds to the catalytic groove of AMPK , 
Regulation by phosphorylation/dephosphorylation
In addition to allosteric activation, AMPK is regulated by reversible phosphorylation ( ). The key step in AMPK activation is Figure 2 its phosphorylation on threonine residue 172 (Thr-172), within the catalytic domain, by upstream kinases. The combination of the allosteric and phosphorylation effects causes >1000-fold increase in kinase activity (compared to up-to fivefold for allosteric activation alone), allowing high sensitivity in responses to small changes in cellular energy status ( Denton, 1998 Omar , 2009 et al. ) . Since, cAMP-stimulated lipolysis in adipocytes was accompanied by an increase in oxidative stress (i.e., an increase Yin , 2003 et al. AMP:ATP ratio), AMPK activation could be a consequence of lipolysis and the associated relative change in cellular energy balance rather than a direct effect of PKA ( ). Similarly, it has been shown that IL-6 activates AMPK in skeletal muscle by Gauthier , 2008 et al. increasing the concentration of cAMP and, secondarily, the AMP:ATP ratio ( ). These data suggest that activation of AMPK complexes may elicit distinct metabolic as well as signaling effects in tissues and cells depending on the expression of different catalytic and regulatory subunits.
Regulation of protein stability
Recent data revealed a new mechanism that regulates AMPK activity independently of AMP and of phosphorylation or dephosphorylation processes. Modulation of AMPK complex stability ubiquitination-mediating degradation has emerged through a via complex containing cell death-inducing DNA fragmentation factor -like effector A (Cidea) and AMPK ( ). Cidea and 
AMPK inhibition in physiology Regulation by nutrient

Inhibition by lipid overload
An increasing body of evidence indicates that dysregulation of AMPK activity and its consequential signaling network may have sustained and deleterious effects at the systemic level that underlie the pathogenesis of metabolic syndrome (Ruderman and Prentki, 2004 upregulation was accounted for decreased AMPK activity in the heart of obese rodents with cardiac lipotoxicity ( ). Wang and Unger, 2005 These data provide new insights into the mechanisms of lipo-regulatory dysfunction, leading to lipid metabolism disorders in obesity.
If decreased AMPK activity contributes to the pathogenesis of obesity, as suggested by dysregulation of AMPK signaling in obese rodent models, one would expect that mice lacking AMPK will be more sensitive to deleterious effects of over-nutrition. Consistent with this hypothesis, whole-body ablation of AMPK 2 activity exacerbates high fat diet-induced obesity, while the glucose disposal rates are adiposity, and impaired insulin and glucose tolerance, however, there was no difference between wild-type and transgenic litter-mates overexpressing an AMPK 2 kinase-dead (KD) in muscle. High-fat feeding decreased insulin-stimulated muscle glucose uptake and α Akt-phosphorylation, while increasing muscle triacylglycerol, diacylglycerol and ceramide. These effects, as well as obesity-induced lipid accumulation and insulin resistance were not exacerbated in AMPK KD mice, suggesting that reduced levels of muscle AMPK 2 did not α promote insulin resistance in the early phase of obesity-related diabetes. Another study by Fujii and coworkers demonstrated that mice overexpressing a muscle-specific KD AMPK 2 Asp157Ala mutation developed more severe muscle insulin resistance after 30 weeks on α high-fat diet ( ). However, the observation that the genotype effect occurred 26 weeks late than the first evidence of Fujii , 2008 et al. glucose intolerance suggested that AMPK did not play a primary role in the development of insulin resistance. Thus, while AMPK function is impaired with severe obesity, it does not appear to influence the development of insulin resistance in diet-induced obesity.
Inhibition by high glucose concentration
AMPK can be negatively regulated by chronic exposure to high glucose. Acute hyperglycemia reduces AMPK activation in muscle, liver ( ) and kidney ( 
-sensing mechanism used by the ventromedial hypothalamus, a key brain region involved in the detection of hypoglycemia (Fan et allosteric inhibitors of AMPK that also inhibit phosphorylation and activation by upstream kinases. AMPK bound to fully synthesized glycogen particle is probably in an active state due to inaccessibility of internal branch points. This will lead to phosphorylation and inhibition of GS, providing feedback inhibition of further extension of glycogen particles. However, when glycogen is depleted, AMPK becomes inhibited after binding to exposed 1 6 branch points. This allows dephosphorylation of GS on site 2, promoting rapid cross-regulation between AMPK and mTOR to control food intake, hypothalamic ATP levels are increased and AMP/ATP ratio reduced after high protein feeding.
Regulation by hormones and cytokines
Inhibition by insulin in the heart
The energy necessary to maintain the myocardial contraction/relaxation cycle is derived from the mitochondrial oxidation of carbohydrates and long chain fatty acids. Under physiological conditions, fatty acid oxidation provides 60 70 of the heart energy -%
requirements (
). This substrate preference can be attributed to inhibition of glucose uptake and catabolism the Bertrand , 2008 et al. via Randle cycle ( ). Following myocardial infarction, fatty acid oxidation accounts for almost all the heart ATP production Randle , 1963 et al. ( ; ) . This over-reliance on fatty acid oxidation is detrimental to functional reperfusion recovery of Neely and Morgan, 1974 Opie, 1975 ischemic hearts ( ; ). Under such conditions, the beneficial effects of insulin are important Lopaschuk , 1990 et al. Lopaschuk , 1993 for maintaining proper cardiac function. Insulin can increase glucose use by the heart both by activating key steps of glycolysis, namely the recruitment of GLUT-4 to the plasma membrane and the activation of 6-phosphofructo- ) resulting in decreased malonyl-CoA, a potent inhibitor of fatty acid transport into the mitochondrial matrix ( Hardie, 1992 McGarry , et al. 
Inhibition by inflammatory signals
Recent studies have suggested AMPK to play a crucial role in the inflammatory signaling pathways. AMPK activity has been shown to be down-regulated upon pro-inflammatory stimulus (LPS) and up-regulated upon anti-inflammatory cytokine stimulation (IL-10 and
TGF-) (
). Also, inhibition of AMPK activity or expression increases the production of TNF , IL-6 and IL-1 upon β Sag , 2008 et al. 
Inhibition of AMPK in the regulation of food intake
Recently, AMPK has emerged as a regulator of appetite. Indeed, hypothalamic AMPK is now recognized not only as a nutrient and glucose sensor in the central nervous system (CNS) but also as a key regulator of appetite. Because the brain has an extremely high metabolic rate and is a high lipid-containing tissue, the distribution of the AMPK isoforms throughout its various areas was considered as an exciting area of research. Turnley and coworkers first reported the cellular distribution of AMPK isoforms in mouse CNS (Turnley et ). They demonstrated that these are widely expressed in neurons and in activated astrocytes. In addition, several groups showed , 1999 al.
that AMPK isoforms are expressed in hypothalamus and hindbrain, both areas controlling food intake ( ). Studies pertaining to Kola, 2008 pharmacological or genetic activation as well as inhibition of hypothalamic AMPK lead to a better knowledge of hypothalamic AMPK function as a regulator of food intake. It was first recognized that hypothalamic AMPK activation by AICAR infusion into the third ventricle significantly increased food intake ( ). Confirming this first study, expression of dominant negative AMPK Andersson , 2004 et al. in the hypothalamus was reported to be sufficient to reduce food intake and body weight, whereas hypothalamic expression of constitutively active AMPK isoform increased both ( ). In contrast with these previous studies, some conflicting Minokoshi , 2004 et al. data came from rodent models, especially 2 catalytic subunit specific knock out in hypothalamic Agouti-related peptide (AgRP) neurons α or in hypothalamic pro-opiomelanocortin (POMC) neurons. Indeed, in contrast to what could be expected from the data previously 9 19 published, AMPK-2 specific deletion in AgRP neurons did not change food intake nor energy expenditure whereas mice were lean. α Furthermore, AMPK-2 specific deletion in POMC neurons unexpectedly increased body weight and adiposity ( ). To explain some of these surprising data, it was argued that AICAR or Compound C (as used previously in many studies) were not specific of AMPK pathway and that genetically modified mice models may provide new insights into hypothalamic AMPK functions. In this regard, study from Claret and coworkers clearly suggests that loss of AMPK in orexigenic (AgRP) neurons leads to reduced body weight whereas lost of this enzyme in anorexigenic (POMC) neurons leads to increased body weight. Importantly, electrophysiological studies showed that leptin or insulin action are both preserved in AMPK 2-deficient POMC or AgRP neurons. In consequence, this paper challenged the α concept of hypothalamic AMPK as a general sensor and integrator of energy homeostasis in the mediobasal hypothalamus.
Hypothalamic AMPK is regulated by various metabolic signals coming from the periphery ( ). It is now well Ahima and Antwi, 2008 accepted that fasting results in activation of AMPK whereas re-feeding inhibits AMPK activity in multiple hypothalamic regions in mice ( ). Specific effects of nutrients and hormones on hypothalamic AMPK activity have been investigated by different groups. Kola, 2008 Peripheral or central hyperglycaemia is known to inhibit AMPK in all brain areas controlling appetite (such as the arcuate nucleus, the ventro-and dorso-mediobasal hypothalamus, the paraventricular nucleus and the lateral hypothalamus ( hyperinsulinaemia, hyperglycaemia and increased secreted leptin. Presumably, leptin promotes loss of body weight by enhancing fat oxidation in peripheral tissues and by decreasing food intake, suggesting that leptin has tissue-specific effects. It is not known if muscular AMPK activation by leptin and concomitant reduction of hypothalamic AMPK activity by leptin are supported by different AMPK isoforms. However, as discussed above, the hypothesis that hypothalamic AMPK could be a key mediator for the control of appetite by leptin has been recently challenged when a normal response to leptin has been described in selective AMPK 2-deficient POMC or AgRP α neurons ( ). Interestingly, it has been shown that like leptin, ciliary neurotrophic factor (CNTF) also suppresses Claret , 2007 et al. hypothalamic AMPK signaling and reduces food intake ( ). Importantly, despite the similarities in signaling Steinberg , 2006b et al. between leptin and CNTF, CNTF-mediated suppression of hypothalamic AMPK is maintained in diet-induced obesity, whereas the effects of leptin on AMPK signaling are blunted. Thus, the capacity of CNTF to bypass leptin resistance highlights its potential role in the therapeutic treatment of obesity. AMPK activity is regulated by cellular energetic status, which can be summarized by the intracellular AMP/ATP ratio. Any modification of glucose and/or lipids availability has consequences on AMPK activity. C75 is a fatty acid synthase (FAS) inhibitor which causes weight loss and anorexia. This effect is linked to increased neuronal ATP content by C75 and reduced level of the phosphorylated AMPK subunit in the hypothalamus ( ). Anorectic effect induced by C75 is based on decreased phosphorylation of Taking together the effects of nutrients, hormones and compounds described above, it can be postulated that hypothalamic AMPK is a key sensor of whole-body energy status and regulates fuel availability and appetite. Nevertheless, many questions have to be solved. The molecular mechanisms involved in the regulation of food intake by hypothalamic AMPK are not clearly understood. It can be noticed that changes in hypothalamic activity AMPK may contribute to modifications of arcuate neuropeptide expression. Thus, reduction of hypothalamic AMPK activity (by glucose, leptin, insulin, C75, -lipoic acid and melanocortin 4 receptor agonists) suppresses expression α of orexigenic neuropeptides, NPY and AgRP in arcuate nucleus. In contrast, increase in hypothalamic AMPK activity (by hypoglycemia, ghrelin, cannabinoids and adiponectin) enhances the expression of orexigenic NPY and AgRP in arcuate nucleus and melanin-concentrating hormone in the lateral hypothalamus ( ). In additional studies, it was shown that Minokoshi , 2004 et al. hypothalamic AMPK and melanocortin pathways are interrelated. Indeed, melanocortin 4 receptor agonists decrease hypothalamic AMPK activity whereas melanocortin receptor antagonists (as AgRP) increase hypothalamic AMPK ( ). In these cases, it is difficult to Kola, 2008 understand if AMPK activity is regulated by AgRP or melanocortin signaling independently of neuronal AMP/ATP ratio changes. Lastly, beyond unspecific effects of AICAR or Compound C, rodent models overexpressing or deleted for hypothalamic AMPK provide evidence of changes of AMPK activity and food intake. However, the extent of physiological relevance of these models could be discussed.
Inhibition by resistin: implication for the regulation of glucose homeostasis
Resistin is a 12,5-kDa cysteine-rich protein secreted by adipose tissue of rodents and macrophages of humans ( Nagaev and Smith, 2001 in the development of diet-induced insulin resistance. Additionally, some studies support a link between deleterious metabolic effects of resistin and reduction of AMPK activity. Indeed, a significant correlation has been shown between plasma resistin levels with high fat feeding (or acute infusion of recombinant resistin), hepatic insulin resistance and diminished AMPK phosphorylation in liver (Muse , et al. ) . Conversely, treatment with resistin specific antisense oligodeoxynucleotide reversed these effects. In addition, mice lacking resistin 2004 exhibit low blood glucose levels after fasting, due to reduced hepatic glucose production ( ). This is partly mediated Banerjee , 2004 et al. by activation of AMPK and decreased expression of gluconeogenic enzymes in the liver. Taken together, these data indicated that resistin is a key promoter of hepatic insulin resistance and that this effect could be partly mediated through reduction of hepatic AMPK activity.
Additional studies suggested that resistin acting on hypothalamus modulates hepatic glucose production. Thus, infusion of resistin in the third cerebral ventricle ( ) or in the mediobasal hypothalamus was sufficient to enhance endogenous glucose production through an icv increase of TNF , IL-6, and SOCS-3 expression and a decrease of AMPK phosphorylation in the liver ( ). Nevertheless, it can be noted that some studies used supra-physiological Palanivel and Sweeney, 2005 concentrations of resistin. This could explain that in a recent study on mouse extensor digitorum longus (EDL), soleus muscles and L6 myotubes, physiological concentrations of resistin impair insulin-stimulated glucose uptake by mechanisms involving reduced plasma membrane GLUT4 translocation but independently of the proximal insulin-signaling cascade, AMPK, and SOCS-3 .
AMPK inhibition in therapeutics Neuroprotection in stroke: slowing down AMPK activation
Lack of blood and oxygen after ischemic stroke causes disruption of cell ion homeostasis and lead to neuronal cell death. To repair the damage and return neurons to homeostasis, a number of energy-consuming processes are activated. Overactivation of these pathways during ischemia can lead to complete energy failure and cell death. Activation of AMPK was initially considered to be an adaptive response due to altered AMP/ATP ratio in response to ischemia, hypoxia, or glucose deprivation ( ; Culmsee , 2001 et al. Gadalla , et al. ;  ) but there has been some discordance about the outcome on cell survival and neuroprotection. 
AMPK inhibition in cancer: a two-edged sword?
Several recent reports support the idea that the stimulation of AMPK with pharmacological compounds exerts antitumoral effect in various experimental settings (reviewed in ( ; ). Furthermore, epidemiological analyses Billaud and Viollet, 2008 Fogarty and indicate that treatment with the anti-diabetic drug metformin may reduce the cancer burden in diabetic type 2 patients (reviewed in ( ; ). These findings have led to the conception that pharmacological activators of Billaud and Viollet, 2008 Fogarty and AMPK may find clinical applications in cancer chemoprevention and therapy. Since the LKB1-AMPK pathway inhibits mTOR, a kinase overactivated in a broad range of tumors, AMPK activators may prove beneficial in a large spectrum of cancers. This idea is reinforced by the observation that metformin is selectively toxic for malignant cells harboring p53-inactivating mutations ( ). Buzzai , 2007 et al. However, during specific stages of the tumorigenic process, activation of AMPK might provide a survival advantage to tumor cells. It is clearly documented that nascent cancer cells and their metastatic counterparts are exposed to harsh microenvironmental conditions since they have to cope with extrinsic cellular stresses such as hypoxia, acidosis, shortage of glucose and nutrients. In this context of energetic stress and hypoxia, AMPK is activated and protects cells from apoptosis as demonstrated for pancreas cancer cells ( ). Kato , 2002 et al. Also, a recent report has provided evidence that the AMPK catalytic activity is triggered under low-oxygen conditions and is critical to promote the growth of xenografted tumors prepared from Ras-transformed mouse embryonic fibroblasts ( ). It is Laderoute , 2006 et al.
thus possible that activation of AMPK is a key event at defined steps of the sequential tumorigenic process. For instance, breast cancer cells overcome anoikis, a cell death mechanism that leads to the self-destruction of epithelial cells detaching from the basement membrane, through an increase of glucose uptake that restores the intracellular level of ATP and reduces reactive oxygen species (Schafer , 2009 et al. ) . AMPK stimulates the transport of glucose through the GLUT1 transporter and may be involved in the capacity of tumors cells to override cell death induced by loss of extracellular matrix attachment. In a larger prospect, the multiple metabolic pathways regulated by AMPK possibly place this kinase as one of the main actors contributing to the metabolic reprogramming known as Warburg effect, which is a hallmark of malignant cells ( ). Thus, it is conceivable that at certain stages of cancer progression, and for Vander Heiden , 2009 et al. some types of malignancies, AMPK inhibition rather than activation may represent a potential way of therapeutic intervention. In any case, the experimental arguments supporting a favoring role for AMPK during oncogenesis call for a cautious evaluation of possible pro-tumoral effects of treatments that aims at activating AMPK in cancer prevention and chemotherapy.
Pharmacological AMPK inhibitor: the hidden side of Compound C
Compound C is a cell-permeable pyrrazolopyrimidine compound that can act as a reversible and ATP-competitive inhibitor of AMPK (
). This compound is being used increasingly to inhibit AMPK in cell-based assays. However, several studies have 
Concluding remarks
Since the initial description of the role of AMPK in modulating energy metabolism (as illustrated by regulation of lipid metabolism), there has been an expanded interest in the role of AMPK in numerous physiological systems. AMPK integrates the activity of several essential processes to maintain energy balance both at the single and the whole body levels. In recent years, additional mechanisms in the AMPK regulation have been discovered and it is clear that multiple pathways for activation or inhibition of AMPK are now possible.
These various stimuli include nutrients, hormones, cytokines, physiological state as well as pathological events. A large body of experimental evidence has clearly shown the therapeutic potential of pharmacological activation of AMPK in order to prevent or reverse metabolic disorders associated with the metabolic syndrome. However, understanding the consequence of AMPK inhibition may suggest novel therapeutic targets in a number of disease conditions. Thus, studies using genetic models with AMPK deficiency will be a great help to define the role of AMPK in regulating physiological responses . in vivo 
Figure 3
Regulation of AMPK activity by inflammatory signals Activation of TLR4 by endotoxin and free fatty acid (FFA) regulates AMPK phosphorylation status through the action of protein phosphatase (PP).
